menu

NEWS

April 26, 2017

John Tucker Appointed as Chief Executive Officer of scPharmaceuticals

April 25, 2017

PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

April 20, 2017

Audentes Therapeutics Announces Pricing of Public Offering of Common Stock

April 20, 2017

First Installation of the World’s Most Responsive Smart-Tinting Glass Unveiled In San Francisco

April 12, 2017

Millendo Therapeutics Appoints Mary Lynne Hedley, Ph.D. and Carole Nuechterlein, J.D. to Board of Directors

April 12, 2017

Nohla Therapeutics Announces Collaboration with University of California, Davis to Optimize Manufacturing Process and Supply Cell Therapy Product for Clinical Trials

April 12, 2017

Spyryx Biosciences Presents Data and Corporate Update at Two Recent Conferences in Support of Clinical Candidate for Cystic Fibrosis

April 04, 2017

CARB-X INJECTS UP TO $48 MILLION TO ACCELERATE FIRST POWERED BY CARB-X PORTFOLIO OF DRUG DISCOVERY AND DEVELOPMENT PROJECTS TO TACKLE ANTIBIOTIC RESISTANCE

April 04, 2017

Homology Medicines Appoints Brad Smith as Chief Financial Officer

April 03, 2017

Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy

March 27, 2017

Rennovia enters piloting stage of its key bio-based HDO platform

March 22, 2017

Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center

March 20, 2017

Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)

March 20, 2017

Viveve Announces Pricing of Public Offering of Shares of Common Stock

February 28, 2017

GenePeeks Announces Additional Partnerships with The Donor Solution and 3 Sisters Surrogacy

February 23, 2017

5AM Founding Partner John Diekman named as new chairman of The Scripps Research Institute in La Jolla

February 21, 2017

CIDARA THERAPEUTICS REPORTS UNFAVORABLE RESULTS OF PHASE 2 RADIANT TRIAL OF CD101 TOPICAL IN VVC

February 21, 2017

Bay Area’s Kinestral, View see clear future in smart windows

February 17, 2017

Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium

February 07, 2017

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017

February 07, 2017

Nohla Therapeutics Appoints Kathleen Fanning as President and Chief Executive Officer

February 06, 2017

GenePeeks Appoints Industry Leader Matt Posard as President and Chief Commercial Officer

February 02, 2017

Kinestral Technologies Raises $65 Million in Series C Funding, Prepares to Launch Halio™, the World’s Most Advanced Smart-Tinting Glass

February 02, 2017

Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome

January 24, 2017

scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

January 24, 2017

GenePeeks Launches Preconception Test for Combined Risk of Passing on More than 1,000 Serious Genetic Diseases

January 23, 2017

Homology Medicines and Ideaya Biosciences featured on Biospace.com’s Top 20 Life Science Startups to Watch in 2017

January 18, 2017

Pulmatrix Drug Candidate Receives “Qualified Infectious Disease Product” (QIDP) Designation from the FDA

January 18, 2017

Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare

January 09, 2017

Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance

January 05, 2017

Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer

January 05, 2017

Aprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco

January 04, 2017

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

December 20, 2016

scPharmaceuticals Initiates Commercial Scale Manufacturing Program for its sc2Wear™ Furosemide Infusor

December 12, 2016

Flexion Therapeutics Submits New Drug Application for Zilretta™ to Treat Knee Osteoarthritis Pain

December 12, 2016

Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin

December 12, 2016

Arvinas Presents Data on Oral Estrogen Receptor PROTAC Degrader at 2016 San Antonio Breast Cancer Symposium

December 09, 2016

Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting

December 05, 2016

Nohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with Innovative Off the Shelf, Universal Donor Cellular Therapy

November 29, 2016

Arvinas Presents Data on its BET PROTAC Degraders at 2016 EORTC-NCI-AACR Symposium

November 29, 2016

Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility

November 29, 2016

PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency

November 10, 2016

CIDARA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS

November 10, 2016

Viveve Announces New Brand Identity GENEVEVE™ by Viveve

November 10, 2016

Viveve® Reports Record Third Quarter Financial Results

November 10, 2016

AUDENTES THERAPEUTICS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

November 08, 2016

PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology

November 07, 2016

PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update

November 07, 2016

Achaogen Reports Third Quarter 2016 Financial Results and Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Plazomicin Program

November 04, 2016

Pulmatrix Reports Third Quarter 2016 Financial Results and Business Update

November 02, 2016

CIDARA THERAPEUTICS AND SQUARE 1 BANK ANNOUNCE $20 MILLION CREDIT FACILITY

October 20, 2016

5AM VENTURES ANNOUNCES TEAM ADDITIONS

October 13, 2016

VIVEVE® ANNOUNCES REGULATORY APPROVAL FOR VIVEVE SYSTEM IN U.A.E. AND LEBANON

October 13, 2016

CIDARA THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK, INCLUDING EXERCISE OF UNDERWRITER’S OPTION TO PURCHASE ADDITIONAL SHARES

October 10, 2016

APREA THERAPEUTICS ANNOUNCES EFFICACY AND SAFETY DATA IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS TREATED WITH APR-246 IN PRESENTATION AT 2016 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING

October 10, 2016

APREA THERAPEUTICS ANNOUNCES FIRST PATIENTS ENROLLED IN PHASE II CLINICAL STUDY OF APR-246 FOR THE TREATMENT OF HIGH-GRADE SEROUS OVARIAN CANCER

October 06, 2016

VIVEVE® ANNOUNCES FDA 510(K) CLEARANCE FOR THE VIVEVE SYSTEM IN THE U.S.

September 21, 2016

CIDARA THERAPEUTICS SELECTS FIRST DEVELOPMENT CANDIDATE FROM ITS CLOUDBREAK™ IMMUNOTHERAPY DISCOVERY PLATFORM

September 19, 2016

FIERCEBIOTECH NAMES IDEAYA BIOSCIENCES AS ONE OF ITS “FIERCE 15” BIOTECH COMPANIES OF 2016

September 19, 2016

SCPHARMACEUTICALS ANNOUNCES PRESENTATIONS ON SUBCUTANEOUS FUROSEMIDE AT HFSA ANNUAL MEETING

September 15, 2016

HOMOLOGY MEDICINES ACQUIRES LICENSE TO NOVEL AAV TECHNOLOGY TO DEVELOP TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS

September 08, 2016

CHRONO THERAPEUTICS RAISES $47.6 MILLION IN SERIES B FINANCING TO ADVANCE ITS CLINICAL PLATFORM FOR PERSONALIZED DRUG THERAPY

September 01, 2016

ACHAOGEN COMPLETES PATIENT ENROLLMENT IN PHASE 3 EPIC CLINICAL TRIAL OF PLAZOMICIN

August 31, 2016

AUDENTES THERAPEUTICS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

August 18, 2016

SPYRYX BIOSCIENCES EXPANDS EXECUTIVE TEAM, APPOINTS PULMONARY INDUSTRY LEADER, ALISTAIR WHEELER, MD, MFPM AS CHIEF MEDICAL OFFICER

August 17, 2016

AUDENTES THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN THE INCEPTUS CLINICAL ASSESSMENT STUDY OF XLMTM

August 11, 2016

CIDARA REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

August 09, 2016

CIDARA THERAPEUTICS ANNOUNCES PRESENTATIONS ADDRESSING VULVOVAGINAL CANDIDIASIS AT UPCOMING IDSOG ANNUAL MEETING

August 08, 2016

CLEAVE BIOSCIENCES RAISES $37 MILLION SERIES B FINANCING

July 27, 2016

MILLENDO THERAPEUTICS ANNOUNCES PUBLICATION OF POSITIVE PHASE 2A DATA FOR MLE4901 FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME

July 21, 2016

GALENICA AND RELYPSA ANNOUNCE AGREEMENT FOR GALENICA TO ACQUIRE RELYPSA

July 19, 2016

AUDENTES THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

July 12, 2016

SUPERNUS PHARMACEUTICALS FOUNDER AND CEO JACK KHATTAR JOINS SCPHARMACEUTICALS BOARD OF DIRECTORS

June 14, 2016

VIVEVE® ANNOUNCES PRICING OF $13.5 MILLION PUBLIC OFFERING OF SHARES OF COMMON STOCK AND NASDAQ UPLISTING

June 09, 2016

CIDARA DOSES FIRST PATIENT IN PHASE 2 TRIAL OF CD101 TOPICAL TO TREAT VULVOVAGINAL CANDIDIASIS

June 07, 2016

ARVINAS PUBLISHES FIRST PEER-REVIEWED, IN VIVO DATA FROM ITS PROPRIETARY PROTAC TECHNOLOGY

June 06, 2016

APREA AB ANNOUNCES EFFICACY AND SAFETY DATA IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS TREATED WITH INVESTIGATIONAL APR-246 PRESENTED AT 2016 ASCO ANNUAL MEETING

June 02, 2016

ACHAOGEN AWARDED $20 MILLION CONTRACT OPTION BY BARDA TO SUPPORT DEVELOPMENT OF PLAZOMICIN FOR MULTI-DRUG RESISTANT GRAM-NEGATIVE INFECTIONS

May 31, 2016

FDA GRANTS QIDP AND FAST TRACK DESIGNATION TO CD101 TOPICAL, CIDARA THERAPEUTICS’ NOVEL ANTIFUNGAL PRODUCT CANDIDATE

May 31, 2016

5AM VENTURES RAISES $285 MILLION LIFE SCIENCE VENTURE CAPITAL FUND

May 17, 2016

PURIGEN BIOSYSTEMS RECEIVES $18.2M IN SERIES A FINANCING LED BY 5AM VENTURES AND ROCHE VENTURE FUND

May 10, 2016

STORA ENSO STRENGTHENS BIO-BASED CHEMICALS DEVELOPMENT AND SIGNS A JOINT TECHNOLOGY DEVELOPMENT AND LICENSE AGREEMENT WITH RENNOVIA

May 09, 2016

EPIRUS ANNOUNCES REPRIORITIZATION OF PIPELINE TO SOLELY FOCUS ON BIOSIMILARS TO TREAT RARE DISEASES AND KEY LEADERSHIP CHANGES

May 03, 2016

IDEAYA BIOSCIENCES RAISES $46 MILLION SERIES A AND RECRUITS LEADERSHIP AND ADVISORY BOARD

May 02, 2016

HOMOLOGY MEDICINES EMERGES WITH NEXT GENERATION GENE EDITING TECHNOLOGY DRIVEN BY INDUSTRY-LEADING TEAM IN RARE DISEASES

April 21, 2016

VIVEVE® ANNOUNCES POSITIVE TOPLINE RESULTS FOR VIVEVE I CLINICAL TRIAL

April 04, 2016

FLEXION THERAPEUTICS ANNOUNCES PRESENTATION OF RESULTS FROM PIVOTAL PHASE 2B AND PHASE 3 CLINICAL TRIALS FOR ZILRETTA™ AT OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 2016 WORLD CONGRESS

March 28, 2016

SCPHARMACEUTICALS ANNOUNCES EXPANSION OF EXECUTIVE TEAM

March 09, 2016

CANCER COMPANY APREA CLOSES EUR 46 MILLION (~USD 51 MILLION) SERIES B FINANCING

March 02, 2016

SCPHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PIVOTAL TRIAL OF SECOND PROGRAM – SUBCUTANEOUS CEFTRIAXONE FOR TREATMENT OF BACTERIAL INFECTIONS

March 02, 2016

ARVINAS APPOINTS ANGELA SHEN AS CHIEF MEDICAL OFFICER

February 03, 2016

PEAR THERAPEUTICS CLOSES $20 MILLION FINANCING

February 03, 2016

VENTUREWIRE: PEAR THERAPEUTICS RAISES $20M FOR DIGITAL SUBSTANCE-ABUSE TREATMENT

January 11, 2016

ACHAOGEN ANNOUNCES ENROLLMENT OF FIRST PATIENT IN EPIC, A PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) WITH PLAZOMICIN

January 05, 2016

AUDENTES THERAPEUTICS APPOINTS SCOTT W. MORRISON TO BOARD OF DIRECTORS

January 05, 2016

MILLENDO LICENSES PHASE 2 POLYCYSTIC OVARY SYNDROME (PCOS) DRUG CANDIDATE FROM ASTRAZENECA AND SECURES SERIES B FINANCING OF $62 MILLION TO ADVANCE PIPELINE OF ENDOCRINE DISORDER THERAPIES

December 17, 2015

5AM VENTURES ANNOUNCES PROMOTIONS AND TEAM EXPANSION

December 04, 2015

JOHNSON & JOHNSON ANNOUNCES COMPLETION OF NOVIRA THERAPEUTICS, INC. ACQUISITION

November 10, 2015

SCPHARMACEUTICALS ANNOUNCES START OF PIVOTAL TRIAL FOR SUBCUTANEOUS DELIVERY OF LEADING ANTIBIOTIC

November 04, 2015

NOVIRA THERAPEUTICS ANNOUNCES ACQUISITION AGREEMENT WITH JOHNSON & JOHNSON

November 04, 2015

SCPHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PIVOTAL TRIAL OF ITS NOVEL SUBCUTANEOUS FUROSEMIDE FORMULATION IN PATIENTS WITH HEART FAILURE

November 02, 2015

CRINETICS PHARMACEUTICALS COMPLETES $40 MILLION SERIES A FINANCING

October 21, 2015

FDA APPROVES NEW DRUG TO TREAT HYPERKALEMIA

October 21, 2015

RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA

October 21, 2015

ARVINAS SECURES $41.6M SERIES B FINANCING – APPOINTS NEW BOARD MEMBERS

October 20, 2015

PORTAL INSTRUMENTS CLOSES A $25 MILLION SERIES B FINANCING TO COMMERCIALIZE ITS TRANSFORMATIVE NEEDLE-FREE DRUG DELIVERY SYSTEM

October 13, 2015

FIERCEBIOTECH: AUDENTES THERAPEUTICS MAY BE EYEING IPO AFTER A $65M CROSSOVER FUND

October 06, 2015

THE MEDICINES COMPANY AND SYMBIO PHARMACEUTICALS ESTABLISH STRATEGIC PARTNERSHIP FOR IONSYS® (FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM) IN JAPAN

October 01, 2015

ARVINAS INKS STRATEGIC LICENSE AGREEMENT WITH GENENTECH

September 30, 2015

FIERCEBIOTECH NAMES ARVINAS AS ONE OF ITS “FIERCE 15” BIOTECH COMPANIES OF 2015

September 29, 2015

PRECISION NANOSYSTEMS RAISES $13.4M IN SERIES A FINANCING

September 25, 2015

BELLEROPHON THERAPEUTICS ANNOUNCES POSITIVE DATA FROM INTERIM ANALYSIS OF PHASE 2 LONG-TERM EXTENSION STUDY OF INOPULSE(R) FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

September 25, 2015

THE MEDICINES COMPANY RECEIVES CHMP POSITIVE OPINION FOR IONSYS® TO TREAT POST-OPERATIVE PAIN IN ADULT PATIENTS

September 09, 2015

EPIRUS BIOPHARMACEUTICALS EXPANDS BIOSIMILAR PIPELINE AND CAPABILITIES THROUGH ACQUISITION OF BIOCEROS

September 01, 2015

AUDENTES THERAPEUTICS ACQUIRES CARDIAC GENE THERAPY COMPANY CARDIOGEN SCIENCES

August 27, 2015

NOVO NORDISK TO ACQUIRE CALIBRIUM LLC AND MB2 LLC

August 26, 2015

BD TO ACQUIRE CELLULAR RESEARCH TO DEVELOP A LEADING GENOMICS PLATFORM FOR SINGLE CELL ANALYSIS

August 11, 2015

5AM VENTURES APPOINTS YUJIRO HATA AS EXECUTIVE-IN RESIDENCE

August 03, 2015

CIDARA THERAPEUTICS INITIATES PHASE 1 STUDY OF LEAD ANTIFUNGAL PRODUCT CANDIDATE CD101 IV

July 14, 2015

EPIRUS BIOPHARMACEUTICALS AND POLPHARMA GROUP ENTER INTO A MULTI-PRODUCT, MULTI-REGION, PROFIT-SHARING COLLABORATION TO ADVANCE BIOSIMILAR PORTFOLIO TARGETING $6 BILLION ADDRESSABLE INNOVATOR MARKET

June 12, 2015

RUTHIGEN AND PULMATRIX STOCKHOLDERS APPROVE MERGER

June 04, 2015

ARVINAS PUBLISHES FIRST PEER-REVIEWED PAPER ON ITS PROPRIETARY PROTAC TECHNOLOGY

May 21, 2015

CHINESE CONSORTIUM ENTERS INTO AGREEMENT TO ACQUIRE AMBRX

May 11, 2015

AUDENTES THERAPEUTICS ANNOUNCES NEW DATA TO BE PRESENTED AT AMERICAN SOCIETY OF GENE AND CELL THERAPY ANNUAL MEETING

May 11, 2015

FDA GRANTS QIDP AND FAST TRACK DESIGNATIONS TO CD101 IV, CIDARA THERAPEUTICS’ LEAD ANTIFUNGAL PRODUCT CANDIDATE

May 07, 2015

SPYRYX BIOSCIENCES SECURES $18 MILLION IN SERIES A FINANCING

April 30, 2015

THE MEDICINES COMPANY ANNOUNCES FDA APPROVAL OF IONSYS® (FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM) FOR THE MANAGEMENT OF ACUTE POST-OPERATIVE PAIN FOR ADULT PATIENTS IN THE HOSPITAL

April 21, 2015

AUDENTES THERAPEUTICS APPOINTS STEPHEN SQUINTO, PH.D. TO ITS BOARD OF DIRECTORS

April 21, 2015

SCPHARMACEUTICALS ANNOUNCES START OF PIVOTAL TRIAL FOR NOVEL FUROSEMIDE SOLUTION FOR SUBCUTANEOUS DELIVERY

April 16, 2015

MALLINCKRODT COMPLETES ACQUISITION OF IKARIA

April 15, 2015

CIDARA THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

April 14, 2015

SCPHARMACEUTICALS ELECTS DOROTHY COLEMAN TO BOARD OF DIRECTORS AND APPOINTS BRIAN PIEKOS AS CHIEF FINANCIAL OFFICER

April 07, 2015

ARVINAS ANNOUNCES STRATEGIC R&D COLLABORATION WITH MERCK TO STUDY NOVEL PROTEIN DEGRADATION TECHNOLOGY

April 07, 2015

VIVEVE COMPLETES ENROLLMENT IN THE VIVEVE I CLINICAL TRIAL

March 17, 2015

XCONOMY: IN MENTAL HEALTH THERAPY, CAUTIOUS STEPS TOWARD THE PHARMACODIGITAL

March 16, 2015

RUTHIGEN AND PULMATRIX ENTER INTO MERGER AGREEMENT

March 10, 2015

PEAR THERAPEUTICS CLOSES FINANCING

March 06, 2015

CETERIX ANNOUNCES PUBLICATION OF STUDIES DEMONSTRATING ADVANTAGES OF MENISCUS REPAIR WITH MINIMALLY INVASIVE ORTHOPAEDIC SUTURING DEVICE

March 05, 2015

MALLINCKRODT PHARMACEUTICALS TO EXPAND HOSPITAL GROWTH PLATFORM WITH IKARIA, INC. ACQUISITION

February 25, 2015

RELYPSA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

February 13, 2015

BELLEROPHON THERAPEUTICS ANNOUNCES PRICING OF ITS INITIAL PUBLIC OFFERING

February 11, 2015

CIDARA THERAPEUTICS COMPLETES $42 MILLION PRIVATE SERIES B FINANCING

February 09, 2015

VIVEVE APPOINTS JAMES ATKINSON CHIEF BUSINESS OFFICER/PRESIDENT

February 05, 2015

CELLULAR RESEARCH UNVEILS MASSIVELY PARALLEL SINGLE-CELL SEQUENCING TECHNOLOGY; ANNOUNCES PARTNERSHIP PROGRAM FOR DRUG DISCOVERY AND DIAGNOSTICS

February 02, 2015

FLEXION THERAPEUTICS INITIATES PHASE 3 CLINICAL TRIAL OF FX006 IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

January 28, 2015

WIRED ARTICLE: THIS WEARABLE HELPS YOU QUIT SMOKING BY DOSING YOU WITH NICOTINE

January 15, 2015

ARVINAS APPOINTS MANUEL LITCHMAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

January 08, 2015

ACHAOGEN ANNOUNCES PLAZOMICIN GRANTED QIDP DESIGNATION BY FDA

January 05, 2015

RELYPSA ANNOUNCES ASSIGNMENT OF OCTOBER 21, 2015 PDUFA DATE FOR NEW DRUG APPLICATION FOR PATIROMER FOR ORAL SUSPENSION

December 17, 2014

FLEXION THERAPEUTICS ANNOUNCES EXERCISE OF UNDERWRITERS’ OVER-ALLOTMENT OPTION AND CLOSING OF PUBLIC OFFERING OF COMMON STOCK

December 17, 2014

RELYPSA TO BE ADDED TO NASDAQ BIOTECHNOLOGY INDEX

December 16, 2014

RELYPSA ANNOUNCES STEPHEN D. HARRISON, M.A., PH.D., JOINS AS SENIOR VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER

December 15, 2014

RELYPSA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR PATIROMER FOR ORAL SUSPENSION TO TREAT HYPERKALEMIA

December 02, 2014

LEONARD SCHAEFFER JOINS SCPHARMACEUTICALS BOARD OF DIRECTORS

December 02, 2014

EPIRUS BIOPHARMACEUTICALS REMICADE® BIOSIMILAR, INFIMAB™, LAUNCHES IN INDIA

December 02, 2014

AUDENTES THERAPEUTICS RAISES $42.5 MILLION IN SERIES B FINANCING

November 17, 2014

DATA FROM EPIRUS’ PHASE 3 STUDY OF BOW015, A BIOSIMILAR INFLIXIMAB, TO BE PRESENTED AS A LATE BREAKING POSTER AT THE AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING

November 17, 2014

RELYPSA ANNOUNCES KEY DATA PRESENTED PRESENTED AT ASN ON LONG-TERM CHRONIC TREATMENT AND EARLY ONSET OF ACTION WITH PATIROMER FOR ORAL SUSPENSION

November 11, 2014

5AM VENTURES ANNOUNCES VENTURE PARTNER AND CFO APPOINTMENTS

November 10, 2014

NOVIRA THERAPEUTICS ANNOUNCES PRESENTATION OF PHASE 1A SAFETY AND PHARMACOKINETIC DATA FOR NVR 3-778

October 22, 2014

RELYPSA SUBMITS NEW DRUG APPLICATION TO U.S. FDA SEEKING APPROVAL FOR PATIROMER FOR ORAL SUSPENSION TO TREAT HYPERKALEMIA

October 01, 2014

AUDENTES THERAPEUTICS ANNOUNCES CONTINUED EXPANSION OF SENIOR MANAGEMENT TEAM

September 25, 2014

EPIRUS AND LIVZON MABPHARM, INC. ENTER COLLABORATION AGREEMENT FOR CHINA

September 23, 2014

EPIRUS ANNOUNCES POSITIVE 58 WEEK FOLLOW UP DATA FOR BOW015 FOR TREATMENT OF RHEUMATOID ARTHRITIS

September 22, 2014

CIDARA THERAPEUTICS – 2014 FIERCE 15

September 17, 2014

ACHAOGEN ANNOUNCES FIRST PATIENT ENROLLMENT IN A PHASE 3 CLINICAL TRIAL OF PLAZOMICIN TO TREAT INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)

September 16, 2014

EPIRUS’ REMICADE® BIOSIMILAR RECEIVES FINAL APPROVALS IN INDIA

September 09, 2014

FLEXION THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. COMPOSITION OF MATTER PATENT FOR LEAD CANDIDATE FX006

September 04, 2014

NOVIRA THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1A CLINICAL STUDY ON NVR-1221 AND COMMENCEMENT OF PHASE 1B CLINICAL STUDIES

September 03, 2014

FLEXION THERAPEUTICS TO START FX006 PHASE 3 PIVOTAL TRIAL IN 2014; FOLLOWING FDA MEETING, DEVELOPMENT PLAN ADVANCED BY ONE YEAR

September 03, 2014

CIDARA THERAPEUTICS TO PRESENT DATA FROM ANTIFUNGAL DRUG DEVELOPMENT PROGRAM AT ICAAC

August 07, 2014

FLEXION THERAPEUTICS REPORTS SECOND-QUARTER 2014 FINANCIAL RESULTS

July 28, 2014

VBI AND PAULSON CAPITAL ANNOUNCE COMPLETION OF MERGER

July 01, 2014

BELLEROPHON THERAPEUTICS NAMES JONATHAN PEACOCK CHAIRMAN AND CHIEF EXECUTIVE OFFICER

June 30, 2014

CIDARA THERAPEUTICS COMPLETES $32 MILLION SERIES A FINANCING

June 19, 2014

RELYPSA ADDS INDUSTRY VETERANS DANIEL K. SPIEGELMAN AND KENNETH J. HILLAN TO ITS BOARD OF DIRECTORS

June 17, 2014

FLEXION THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2A PHARMACOKINETIC TRIAL WITH LEAD COMPOUND FX006

June 12, 2014

CHRONO THERAPEUTICS, INVENTOR OF WEARABLE “SMART” SMOKING CESSATION TECHNOLOGY, SECURES $32 MILLION IN SERIES A FINANCING

June 11, 2014

PHASE 3 DATA DEMONSTRATE COMPARABILITY OF EPIRUS’ BOW015 TO REMICADE® FOR TREATMENT OF RHEUMATOID ARTHRITIS

May 20, 2014

RELYPSA ANNOUNCES COMMERCIAL MANUFACTURING AGREEMENT WITH DSM FINE CHEMICALS

May 19, 2014

AUDENTES THERAPEUTICS ANNOUNCES SIX ABSTRACTS TO BE PRESENTED AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY MEETING MAY 21-24, 2014

May 09, 2014

PAULSON CAPITAL AND VARIATION BIOTECHNOLOGIES ENTER INTO MERGER AGREEMENT

May 01, 2014

CETERIX ANNOUNCES RESULTS FROM BIOMECHANICAL STUDIES OF MINIMALLY INVASIVE ORTHOPAEDIC SUTURING DEVICE

April 30, 2014

FLEXION THERAPEUTICS INITIATES A PHASE 2B CONFIRMATORY DOSE-RANGING TRIAL WITH LEAD COMPOUND FX006

April 16, 2014

EPIRUS CLOSES $36 MILLION SERIES B FINANCING

April 16, 2014

RELYPSA, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK

April 02, 2014

RELYPSA NAMES SYLVIA R. WHEELER V.P. INVESTOR RELATIONS AND CORPORATE AFFAIRS

March 27, 2014

FIERCEBIOTECH: RUIYI BANKS $15M FROM A-LIST BACKERS TO AMP UP CHINESE R&D

March 25, 2014

scPHARMACEUTICALS COMPLETES $16.0 MILLION SERIES A FINANCING FOR DEVELOPMENT OF TWO PRODUCT CANDIDATES

March 20, 2014

JOHNSON MATTHEY DAVY TECHNOLOGIES LTD. AND RENNOVIA, INC. TO DEVELOP AND COMMERCIALIZE PRODUCTION TECHNOLOGY FOR BIO-BASED GLUCARIC ACID AND ADIPIC ACID

March 17, 2014

ACHAOGEN ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND EXERCISE OF UNDERWRITERS’ OVER-ALLOTMENT OPTION TO PURCHASE ADDITIONAL SHARES

March 13, 2014

NATURE BIOTECHNOLOGY’S ACADEMIC SPINOUTS OF 2013

March 13, 2014

NOVIRA NAMES CHRISTIAN S. SCHADE CHIEF EXECUTIVE OFFICER

March 12, 2014

ACHAOGEN ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

March 04, 2014

AUDENTES THERAPEUTICS ANNOUNCES SIGNIFICANT ADDITIONS TO LEADERSHIP TEAM

February 20, 2014

ACHAOGEN ANNOUNCES KEY APPOINTMENTS TO LEADERSHIP TEAM AND BOARD

February 13, 2014

FLUIDIGM COMPLETES ACQUISITION OF DVS SCIENCES

February 12, 2014

ADM INVESTS $25M IN RENNOVIA: THE COMPLETE STORY

February 11, 2014

ADM INVESTS IN RENNOVIA, INC.

February 11, 2014

FLEXION THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

February 05, 2014

AUDENTES THERAPEUTICS AND GENETHON ANNOUNCE AGREEMENT TO DEVELOP TREATMENT FOR SEVERE GENETIC DISEASE X-LINKED MYOTUBULAR MYOPATHY

February 04, 2014

RELYPSA COMPLETES ENROLLMENT OF PHASE 1 ONSET-OF-ACTION STUDY FOR PATIROMER

January 29, 2014

FLUIDIGM AND DVS SCIENCES ANNOUNCE AGREEMENT FOR FLUIDIGM TO ACQUIRE DVS SCIENCES – CREATING A SINGLE-CELL TECHNOLOGY POWERHOUSE

January 13, 2014

RELYPSA PROVIDES CORPORATE UPDATE

January 09, 2014

EPIRUS AND RANBAXY ANNOUNCE SIGNING OF BOW015 LICENSING PARTNERSHIP FOR BROAD RANGE OF TERRITORIES

January 09, 2014

5AM VENTURES ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS

December 24, 2013

IKARIA SHAREHOLDERS LED BY NEW MOUNTAIN CAPITAL REACH AGREEMENT TO SPLIT IKARIA INTO TWO COMPANIES

December 12, 2013

THE MEDICINES COMPANY AGREES TO ACQUIRE INCLINE THERAPEUTICS, INC.

December 10, 2013

KALOBIOS ANNOUNCES PRELIMINARY PHASE 1 RESULTS IN ADVANCED HEMATOLOGIC MALIGNANCIES WITH KB004, AN ANTI-EPHA3 MONOCLONAL ANTIBODY

December 03, 2013

5AM VENTURES RAISES $250 MILLION LIFE SCIENCE VENTURE CAPITAL FUND

November 20, 2013

RELYPSA, INC. ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING

October 28, 2013

PULMATRIX ANNOUNCES POSITIVE RESULTS FROM INITIAL STAGE OF PHASE IB CLINICAL STUDY OF PUR0200 IN COPD PATIENTS

October 22, 2013

EPIRUS AND ORYGEN BIOTECNOLOGIA ANNOUNCE SIGNING OF MULTIPRODUCT BIOSIMILAR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COLLABORATION FOR BRAZIL

October 17, 2013

BIODESY INC. COMPLETES $15.0 MILLION SERIES A FINANCING AND APPOINTS GREG YAP AS CHIEF EXECUTIVE OFFICER

October 17, 2013

RELYPSA REPORTS POSITIVE TOPLINE RESULTS FOR ITS 52-WEEK PHASE 2B TRIAL OF PATIROMER

October 10, 2013

RELYPSA REPORTS POSITIVE TO-LINE RESULTS FOR THE SECOND PART OF ITS TWO-PART PIVOTAL PHASE 3 TRIAL OF PATIROMER

September 30, 2013

RELYPSA ADDS RENAL INDUSTRY VETERAN JOHN BUTLER TO BOARD OF DIRECTORS

September 26, 2013

KALOBIOS PHARMACEUTICALS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK

September 26, 2013

ARVINAS SECURES $18.25 MILLION TO ADVANCE CLINICAL PROGRAMS FOCUSED ON PROTEIN DEGRADATION

September 23, 2013

ACHAOGEN ANNOUNCES AGREEMENT WITH FDA ON A SPECIAL PROTOCOL ASSESSMENT FOR A PHASE 3 CLINICAL TRIAL OF PLAZOMICIN TO TREAT INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)

September 18, 2013

KALOBIOS’ KB001 ANTI-PSEUDOMONAS ANTIBODY STUDY PUBLISHED IN PEDIATRIC PULMONOLOGY

September 10, 2013

RELYPSA REPORTS POSITIVE TOP-LINE RESULTS FOR THE FIRST PART OF ITS TWO-PART PIVOTAL PHASE 3 TRIAL OF PATIROMER

August 28, 2013

EPIRUS BIOPHARMACEUTICALS ANNOUNCES POSITIVE PHASE 3 DATA SUPPORTING BIOSIMILARITY OF BOW-015 TO REMICADE®

August 20, 2013

AMBRX APPOINTS PETER KIENER, PH.D., AS CHIEF SCIENTIFIC OFFICER

August 19, 2013

KALOBIOS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS

August 07, 2013

KALOBIOS APPOINTS V. BRYAN LAWLIS, JR., PH.D. TO BOARD OF DIRECTORS

July 30, 2013

REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAV™ VECTORS

July 18, 2013

AUDENTES THERAPEUTICS RAISES $30 MILLION IN SERIES A FINANCING

July 16, 2013

CETERIX ANNOUNCES U.S. LAUNCH OF NOVEL DEVICE FOR MINIMALLY INVASIVE ORTHOPAEDIC PROCEDURES

June 26, 2013

FLEXION’S FX006 DEMONSTRATES SUPERIOR PAIN RELIEF COMPARED TO STANDARD-OF-CARE IN PHASE 2B OSTEOARTHRITIS TRIAL

June 14, 2013

AMBRX AND ZHEJIANG MEDICINE CO., LTD. FORM COLLABORATION TO DEVELOP AND COMMERCIALIZE AMBRX’S ANTIBODY DRUG CONJUGATE FOR BREAST CANCER

June 10, 2013

PEARL THERAPEUTICS TO BE ACQUIRED BY ASTRAZENECA FOR UP TO $1.15 BILLION

May 30, 2013

PEARL THERAPEUTICS NAMED WINNER OF 2013 TIE50 “TOP STARTUP” AT TIECON 2013

May 15, 2013

RELYPSA ANNOUNCES APPOINTMENT OF JOHN ORWIN AS CHIEF EXECUTIVE OFFICER

May 13, 2013

RELYPSA COMPLETES PATIENT ENROLLMENT IN PIVOTAL PHASE 3 PROGRAM FOR THE TREATMENT OF HYPERKALEMIA

May 13, 2013

PEARL THERAPEUTICS INITIATES PT003 PHASE 3 PROGRAM FOR THE TREATMENT OF INDIVIDUALS WITH MODERATE-TO-SEVERE COPD

May 04, 2013

DVS SCIENCES INTRODUCES THE CYTOF® 2 MASS CYTOMETER AND NEW MAXPAR® PANEL KITS FOR TRANSFORMATIONAL HIGH-PARAMETER SINGLE CELL ANALYSIS

May 03, 2013

AMBRX INITIATES COLLABORATION WITH BRISTOL-MYERS SQUIBB FOR DISCOVERY, DEVELOPMENT OF NEXT-GENERATION ANTIBODY DRUG CONJUGATES

May 03, 2013

BMS PARTNERS AGAIN WITH AMBRX, IN UP-TO-$112M-AND-UP ADC COLLABORATION

April 24, 2013

ACHAOGEN AWARDED $60M CONTRACT OPTION BY BARDA FOR THE CLINICAL DEVELOPMENT OF PLAZOMICIN

April 09, 2013

IGENICA APPOINTS THI-SAU MIGONE, PH.D., AS CHIEF SCIENTIFIC OFFICER

April 09, 2013

CLEAVE BIOSCIENCES ADDS NEW INVESTOR AND $10 MILLION TO SERIES A FINANCING

April 04, 2013

ASTELLAS AND AMBRX INITIATE COLLABORATION FOR DISCOVERY AND DEVELOPMENT OF NEXT GENERATION ANTIBODY DRUG CONJUGATES FOR ONCOLOGY

March 25, 2013

CETERIX ORTHOPAEDICS ARTICLE IN START-UP: SUTURE SYSTEM FOR ARTHROSCOPIC PROCEDURES, BY BOB KRONEMYER

March 25, 2013

NOVIRA THERAPEUTICS COMPLETES $25 MILLION SERIES A FINANCING

February 28, 2013

BIOTIE: SELINCRO (NALMEFENE) RECEIVES EUROPEAN MARKETING AUTHORIZATION

February 26, 2013

UCB TO LICENSE WORLDWIDE RIGHTS TO TOZADENANT IN PARKINSON’S DISEASE FROM BIOTIE

February 26, 2013

KALOBIOS PRESENTS CLINICAL RESULTS WITH ANTI-GM-CSF ANTIBODY IN PERSISTENT ASTHMA

January 31, 2013

KALOBIOS PHARMACEUTICALS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

January 22, 2013

CETERIX ORTHOPAEDICS COMPLETES $19.5 MILLION SERIES B FINANCING

January 10, 2013

KALOBIOS INITIATES PHASE 2 STUDY WITH KB001-A HUMANEERED® MONOCLONAL ANTIBODY IN CYSTIC FIBROSIS PATIENTS

January 07, 2013

AMBRX APPOINTS LAWSON MACARTNEY, PH.D., DVM, CHIEF EXECUTIVE OFFICER

January 04, 2013

EPIRUS BIOPHARMACEUTICALS, INC. ANNOUNCES POSITIVE PHASE 1 DATA FOR BOW-015

December 17, 2012

FLEXION’S FX006 ACHIEVES PROLONGED THERAPEUTIC CONCENTRATIONS IN JOINTS OF OSTEOARTHRITIS PATIENTS

December 14, 2012

BIOTIE: SELINCRO(TM) (NALMEFENE) RECEIVES POSITIVE OPINION FOR APPROVAL IN THE EUROPEAN UNION

December 11, 2012

BIOTIE’S TOZADENANT (SYN115) MEETS PRIMARY AND MULTIPLE SECONDARY ENDPOINTS IN PHASE 2B STUDY IN PARKINSON’S DISEASE

December 04, 2012

FLEXION THERAPEUTICS SECURES $20 MILLION IN SERIES B FINANCING

November 13, 2012

PEARL THERAPEUTICS RAISES $65 MILLION SERIES D TO START PT003 PHASE 3

November 04, 2012

TAKEDA TO ACQUIRE ENVOY THERAPEUTICS, INC.

October 11, 2012

C. ROBERT KIDDER JOINS BOARD OF DIRECTORS OF WILDCAT DISCOVERY TECHNOLOGIES, INC.

October 05, 2012

KALOBIOS PHARMACEUTICALS FILES REGISTRATION STATEMENT FOR PROPOSED IPO

October 04, 2012

ANAPHORE ANNOUNCES NAME CHANGE TO RUIYI AND NEW ADDITIONS TO SHANGHAI MANAGEMENT TEAM

October 04, 2012

RUIYI (FORMERLY ANAPHORE) AND ARGEN-X ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR ARGX-109, A NOVEL ANTI-IL-6 ANTIBODY

September 26, 2012

WILDCAT DISCOVERY TECHNOLOGIES ENTERS JOINT DEVELOPMENT AGREEMENT WITH JAPAN’S ASAHI KASEI CORP. FOR RECHARGEABLE BATTERY TECHNOLOGY

September 18, 2012

IGENICA APPOINTS MARY HAAK-FRENDSCHO, PH.D., AS CHIEF EXECUTIVE OFFICER

September 14, 2012

CYSTIC FIBROSIS FOUNDATION THERAPEUTICS AND PULMATRIX INITIATE COLLABORATION TO ACCELERATE PUR118 IN THE TREATMENT OF CYSTIC FIBROSIS

September 13, 2012

PEARL THERAPEUTICS COMPLETES PHASE 2B STUDY OF GLYCOPYRROLATE, DEFINES DOSE-RESPONSE CURVE AND IDENTIFIES OPTIMAL DOSE OF PT001

September 11, 2012

KALOBIOS INITIATES PHASE 2 STUDY WITH KB003 HUMANEERED™ MONOCLONAL ANTIBODY IN SEVERE ASTHMA

September 07, 2012

BIOTIE HAS COMPLETED A DIRECTED SHARE ISSUE OF EUR 20 MILLION TO INSTITUTIONAL AND STRATEGIC INVESTORS

September 06, 2012

KALOBIOS COMPLETES DEBT FINANCING OF UP TO $15 MILLION – DEBT FINANCING FOLLOWS $20.25 MILLION IN GROSS EQUITY RAISED IN SECOND QUARTER

August 27, 2012

GENOMEWEB/PROTEOMONITOR ARTICLE: NOLAN LAB PROFILES SMALL-MOLECULE INHIBITORS USING NEW MULTIPLEXING METHOD FOR DVS SCIENCES’ CYTOF

August 24, 2012

NOVIRA THERAPEUTICS SECURES $23 MILLION SERIES A FINANCING TO ADVANCE DEVELOPMENT OF ANTIVIRALS FOR TREATMENT OF CHRONIC HEPATITIS B AND HIV INFECTIONS

August 15, 2012

RELYPSA ANNOUNCES $80 MILLION PRIVATE FINANCING TRANSACTION

August 03, 2012

ATTEROCOR LAUNCHES INNOVATIVE COMPANY FOCUSED ON ACCELERATED DEVELOPMENT OF TREATMENT FOR ADRENAL CANCER; SECURES $16 MILLION SERIES A FINANCING

July 10, 2012

JEFF COOPER JOINS KALOBIOS AS CHIEF FINANCIAL OFFICER

July 07, 2012

LUNDBECK HAS MADE EUR 10 MILLION EQUITY INVESTMENT IN BIOTIE AND THE PARTIES AMEND THE SELINCRO LICENSING AGREEMENT REGARDING TERRITORIES OUTSIDE THE EU AND US

July 05, 2012

BIOTIE COMPLETES ENROLLMENT IN PHASE 2B TRIAL OF TOZADENANT IN PARKINSON’S DISEASE

June 25, 2012

KALOBIOS’ KB001 DEMONSTRATES SAFETY, POTENTIAL AS NEW APPROACH TO PREVENTING PSEUDOMONAS VENTILATOR ASSOCIATED PNEUMONIA

June 25, 2012

TELEFLEX ACQUIRES INNOVATIVE TECHNOLOGY TO REDUCE BIOLOGICAL FORMATION ON MEDICAL DEVICES

June 18, 2012

AMBRX COLLABORATES WITH MERCK TO DESIGN AND DEVELOP BIOLOGIC DRUG CONJUGATES

June 18, 2012

PATRICIA SCHELLER NAMED CEO OF VIVEVE, INC.

June 12, 2012

IGENICA CLOSES $33 MILLION IN SERIES C FUNDING

June 07, 2012

KALOBIOS APPOINTS NÉSTOR MOLFINO AS CHIEF MEDICAL OFFICER

May 30, 2012

FLEXION’S LEAD OSTEOARTHRITIS DRUG CANDIDATE DEMONSTRATES SIGNIFICANT, PROLONGED IMPROVEMENT IN PAIN AND FUNCTION IN PHASE 2 TRIAL

May 28, 2012

THE VIVEVE SYSTEM RECEIVES HEALTH CANADA MEDICAL DEVICE LICENSE TO NON-SURGICALLY TREAT VAGINAL LAXITY FOLLOWING CHILDBIRTH

May 21, 2012

PEARL THERAPEUTICS RECEIVES TIE50 AWARD FROM GLOBAL ENTREPRENEURSHIP NETWORK

May 15, 2012

WILDCAT DISCOVERY TECHNOLOGIES ARTICLE IN MAY/JUNE 2012 TECHNOLOGY REVIEW

May 15, 2012

ACHAOGEN ANNOUNCES ALL OBJECTIVES MET IN PHASE 2 PLAZOMICIN COMPLICATED URINARY TRACT INFECTIONS STUDY AND START OF FIRST-IN-HUMAN STUDY WITH ACHN-975

May 14, 2012

PEARL THERAPEUTICS PHASE 2B TWICE-DAILY DOSING DATA SUGGEST MORNING AND EVENING BENEFIT OF PT003 IN PATIENTS WITH COPD

May 07, 2012

MICHAEL J. FOX FOUNDATION EXPANDS FUNDING TO ENVOY

April 27, 2012

WILDCAT DISCOVERY TECHNOLOGIES NAMED ONE OF TECHNOLOGY REVIEW’S 2012 TOP 50 MOST INNOVATIVE COMPANIES

March 22, 2012

ANAPHORE ANNOUNCES ACQUISITION OF RUIYI IN SHANGHAI CHINA FOR GPCR BIOLOGICS DRUG DISCOVERY PLATFORM

March 13, 2012

FLEXION ARTICLE: COULD THIS BE ORTHOPEDICS’ FUTURE?, ORTHOPEDICS THIS WEEK, 8 (9)

March 05, 2012

DATA PRESENTED AT THE 2012 EUROPEAN CONGRESS OF PSYCHIATRY SHOWING THAT SELINCRO(TM) REDUCES TOTAL ALCOHOL CONSUMPTION BY TWO-THIRDS ON AVERAGE AFTER SIX MONTHS OF TREATMENT

March 01, 2012

BIOTIE SUCCESSFULLY COMPLETES IMAGING STUDY WITH SYN120

December 14, 2011

CLINICAL NEUROSCIENTIST, WILLIAM Z. POTTER, M.D., PH.D., JOINS ENVOY’S ADVISORY BOARD

December 07, 2011

PEARL THERAPEUTICS REPORTS POSITIVE PHASE 2B RESULTS OF PT001 IN PATIENTS WITH COPD

December 05, 2011

DVS SCIENCES APPOINTS JOSEPH VICTOR AS PRESIDENT AND CEO

October 11, 2011

CLEAVE BIOSCIENCES RAISES $42 MILLION IN SERIES A FINANCING FOR NOVEL CANCER THERAPIES

October 10, 2011

INCLINE ADVANCES PAIN MED, SECURES SECOND TRANCHE OF $50M FINANCING

September 28, 2011

ACHAOGEN APPOINTS CHIEF MEDICAL OFFICER KENNETH HILLAN TO CHIEF EXECUTIVE OFFICER

September 26, 2011

PEARL THERAPEUTICS’ BRONCHODILATOR COMBINATION PT003 PROVIDES SUPERIOR INSPIRATORY CAPACITY COMPARED TO SPIRIVA®

September 22, 2011

BRISTOL-MYERS SQUIBB AND AMBRX ANNOUNCE COLLABORATION FOR NOVEL BIOLOGICS PROGRAMS IN DIABETES AND HEART FAILURE

September 06, 2011

FIERCEBIOTECH NAMES PEARL THERAPEUTICS A 2011 FIERCE 15 BIOTECH

August 31, 2011

ENVOY GARNERS FLORIDA GOVERNOR’S 2011 BUSINESS DIVERSIFICATION AWARD

August 30, 2011

PEARL THERAPEUTICS ANNOUNCES POSITIVE RESULTS FOR PHASE 2B DOSE-RANGING STUDY OF FORMOTEROL MDI

August 15, 2011

PULMATRIX SECURES A $14 MILLION FINANCING TO ADVANCE CLINICAL PROGRAMS IN COPD AND CYSTIC FIBROSIS

August 05, 2011

BIOTIE THERAPIES CORP. INTERIM REPORT 1 JANUARY – 30 JUNE 2011

July 25, 2011

BIOTIE ADVANCES CLINICAL PROGRAM FOR SYN120 WITH IMAGING STUDY AT JOHNS HOPKINS CENTER OF EXCELLENCE

July 14, 2011

DVS SCIENCES RAISES $14.6 MILLION IN SERIES A FINANCING TO ADVANCE COMMERCIALIZATION OF NOVEL SINGLE-CELL ANALYSIS TECHNOLOGY

July 11, 2011

VIVEVE SPONSORS STUDY IN JAPAN FOR NEW PROCEDURE TO TREAT VAGINAL LAXITY

June 28, 2011

RELYPSA BEGINS TREATMENT IN AMETHYST-DN TRIAL OF RLY5016 FOR HYPERKALEMIA IN DIABETIC NEPHROPATHY PATIENTS WITH CHRONIC KIDNEY DISEASE

June 20, 2011

ANAPHORE APPOINTS PAUL A. GRAYSON PRESIDENT AND CEO

June 16, 2011

PEARL THERAPEUTICS ADVANCES ITS LONG-ACTING BRONCHODILATOR COMBINATION PRODUCT CANDIDATE INTO FOUR ADDITIONAL PHASE 2 STUDIES

May 18, 2011

PEARL THERAPEUTICS’ PHASE 2B RESULTS SHOW A 50% IMPROVEMENT IN LUNG FUNCTION WITH PT003 COMPARED TO SPIRIVA® AND FORADIL® IN PATIENTS WITH COPD

May 05, 2011

PEARL THERAPEUTICS HIGHLIGHTS ITS POROUS PARTICLE COSUSPENSION PLATFORM, DEMONSTRATING UNIVERSAL APPLICABILITY ACROSS MULTIPLE DRUG CLASSES AND COMBINATION PRODUCTS

April 29, 2011

PEARL THERAPEUTICS TO PRESENT COMPLETE PT003 RESULTS FROM PHASE 2B COPD STUDY IN A LATE-BREAKER SESSION AT THE AMERICAN THORACIC SOCIETY ANNUAL MEETING

April 07, 2011

BIOTIE ANNOUNCES START OF PHASE 2B TRIAL OF SYN115 IN PARKINSON’S DISEASE

March 24, 2011

VBI PROGRESSING WITH VACCINES THAT DON’T REQUIRE REFRIGERATION

March 23, 2011

KALOBIOS INITIATES PHASE 1 CLINICAL TRIAL OF KB004 IN EPHA3-EXPRESSING HEMATOLOGIC MALIGNANCIES

March 14, 2011

WILDCAT DISCOVERY TECHNOLOGIES DISCLOSES FUNDAMENTAL ADVANCES IN RECHARGEABLE BATTERY MATERIALS TECHNOLOGY

February 02, 2011

THE ACQUISITION OF SYNOSIA THERAPEUTICS HOLDING AG COMPLETED

February 02, 2011

MARCADIA MAY FETCH UP TO $537 MILLION IN SALE

January 10, 2011

BIOTIE AND SYNOSIA TO COMBINE TO CREATE A LEADING CNS DEVELOPMENT COMPANY

December 30, 2010

ROCHE ACQUIRES MARCADIA BIOTECH

December 13, 2010

ANAPHORE ENTERS R&D PARTNERSHIP WITH MITSUBISHI TANABE PHARMA TO DEVELOP AND COMMERCIALIZE NOVEL PROTEIN PHARMACEUTICALS FOR AUTOIMMUNE DISORDERS

December 13, 2010

SEMPRUS BIOSCIENCES LANDS ANOTHER $18M

December 01, 2010

GROUND BREAKING DATA ON SYNOSIA’S INVESTIGATIONAL NEW PARKINSON’S DRUG PUBLISHED IN THE JOURNAL OF NEUROSCIENCE

December 01, 2010

PEARL THERAPEUTICS’ PT003 COMBINATION THERAPY FOR COPD DEMONSTRATES SUPERIOR BRONCHODILATION COMPARED TO SPIRIVA® AND FORADIL® IN RANDOMIZED PHASE 2B STUDY

November 30, 2010

IKARIA® BEGINS ENROLLMENT OF PIVOTAL TRIAL FOR LUCASSIN®

November 08, 2010

ANAPHORE ARTICLE IN NATURE BIOTECHNOLOGY 28, 1143 (2010)

October 19, 2010

PEARL THERAPEUTICS RAISES $69 MILLION SERIES C FINANCING

October 14, 2010

RENNOVIA ARTICLE IN SPECIALITY CHEMICALS MAGAZINE, ONLINE EDITION: SAME DIFFERENCE

October 12, 2010

UCB AND SYNOSIA THERAPEUTICS SIGN STRATEGIC ALLIANCE IN NEUROLOGY

October 12, 2010

SYNOSIA THERAPEUTICS RAISES $30M IN SERIES C FINANCING

October 08, 2010

TAKEDA AND ENVOY FORM SCHIZOPHRENIA RESEARCH ALLIANCE

September 29, 2010

SYNOSIA PRESENTS DATA FROM CLINICAL TRIAL OF SYN-118 AS A NEW TREATMENT FOR PARKINSON’S DISEASE

September 28, 2010

RENNOVIA ARTICLE IN ICIS CHEMICAL BUSINESS: BIO-ADIPIC ACID PREPARES FOR ENTRY

September 22, 2010

SEMPRUS BIOSCIENCES AWARDED $500,000 NATIONAL SCIENCE FOUNDATION GRANT

September 20, 2010

RENNOVIA ARTICLE IN C & E NEWS: CATALYZING BIOBASED CHEMICALS

September 15, 2010

POSITIVE PHASE 2 DATA FOR RLY5016 PRESENTED IN LATE-BREAKER SESSION AT HEART FAILURE SOCIETY OF AMERICA MEETING

September 13, 2010

RELYPSA RAISES $70 MILLION IN SERIES B FINANCING

September 09, 2010

ACHAOGEN TO PRESENT NEW DATA ON ACHN-490 AT THE 50TH ANNUAL ICAAC MEETING

August 30, 2010

ACHAOGEN AWARDED CONTRACT WORTH UP TO $64 MILLION BY BARDA FOR THE DEVELOPMENT OF ACHN-490

August 17, 2010

KALOBIOS, SEEKING TO APPLY ANTIBODIES BEYOND CANCER, SETS SIGHT ON KILLING DEADLY LUNG INVADER

August 12, 2010

VIVEVE-SPONSORED RESEARCH TO BE PUBLISHED IN JOURNAL OF SEXUAL MEDICINE

July 15, 2010

IKARIA® NAMES CHIEF SCIENCE OFFICER

July 13, 2010

VIVEVE-SPONSORED RESEARCH ACCEPTED FOR PRESENTATION AT TWO PRESTIGIOUS INTERNATIONAL CONFERENCES

July 08, 2010

IKARIA® NAMES NEW CHIEF FINANCIAL OFFICER

June 28, 2010

MARCADIA AND LILLY SIGN DEVELOPMENT, LICENSE AGREEMENT FOR NOVEL GLUCAGON PROGRAM IN SEVERE HYPOGLYCEMIA

June 22, 2010

INCLINE THERAPEUTICS RAISES $43 MILLION, SIGNS ACQUISITION OPTION

June 15, 2010

WOMEN’S HEALTH COMPANY VIVEVE SPONSORS AWARD WINNING ABSTRACT AT ACOG

June 08, 2010

IKARIA® APPOINTS CHIEF MEDICAL OFFICER

June 05, 2010

SEMPRUS BIOSCIENCES SELECTED AS ONE OF THE “50 COMPANIES TO WATCH” IN MD+DI JUNE ISSUE

June 01, 2010

IKARIA® NAMES NEW HEAD OF RESEARCH & DEVELOPMENT

May 17, 2010

ANTI-PSEUDOMONAS ACTIVITY OF KALOBIOS’ / SANOFI PASTEUR’S KB001 MAY PREVENT SERIOUS LUNG INFECTIONS AND LIMIT DAMAGE INFLAMMATION

May 05, 2010

PEARL THERAPEUTICS’ BRONCHODILATOR COMBINATION THERAPEUTIC FOR COPD TO BE PRESENTED AT THE AMERICAN THORACIC SOCIETY ANNUAL MEETING

April 14, 2010

SYNOSIA THERAPEUTICS’ SYN-115 IMPROVES MOTOR AND NON-MOTOR FUNCTION IN PATIENTS WITH MILD-TO-MODERATE PARKINSON’S DISEASE

April 13, 2010

ENTREMED INITIATES PHASE 2 STUDY FOR ENMD-2076 IN OVARIAN CANCER

April 07, 2010

ACHAOGEN COMPLETES $56 MILLION SERIES C FINANCING

March 30, 2010

IKARIA® ACQUIRES NEW DRUG APPLICATION FOR LUCASSIN®

March 29, 2010

PEARL THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 1 TRIAL OF PT003, A BRONCHODILATOR COMBINATION THERAPEUTIC FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND INITIATION OF PHASE 2B TRIAL

February 17, 2010

MARCADIA INITIATES PHASE I CLINICAL TRIAL OF GLP-1/GIP DUAL AGONIST MAR701

February 01, 2010

SYNOSIA ANNOUNCES POSITIVE INTERIM RESULTS FOR POTENTIAL FIRST-IN-CLASS TREATMENT FOR PARKINSON’S DISEASE

February 01, 2010

PEARL THERAPEUTICS RAISES $15 MILLION TO ADVANCE PT003, LAMA/LABA COMBINATION BRONCHODILATOR FOR COPD, INTO PHASE 2B STUDY

January 29, 2010

FLEXION THERAPEUTICS ANNOUNCES AGREEMENTS WITH FOUR MAJOR PHARMACEUTICAL COMPANIES

January 26, 2010

ENVOY ENTERS DIABETES AND OBESITY COLLABORATION WITH MERCK & CO., INC.

January 11, 2010

KALOBIOS PARTNERS WITH SANOFI PASTEUR ON NOVEL PREVENTION AND TREATMENT FOR PSEUDOMONAS AERUGINOSA

January 04, 2010

PEARL THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 2A TRIAL OF FORMOTEROL INHALATION AEROSOL IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

December 15, 2009

ENTREMED FOCUSES ON DEVELOPMENT OF ENMD-2076

December 09, 2009

ENTREMED INITIATES ENMD-2076 CLINICAL TRIAL IN MULTIPLE MYELOMA

December 07, 2009

5AM VENTURES RAISES $200M FOR 3RD LIFE SCIENCE VENTURE CAPITAL FUND

November 16, 2009

EMERGING DRUG DEVELOPER: FLEXION THERAPEUTICS – A RUTHLESS PURSUIT OF THE BOLD EXPERIMENT

November 09, 2009

WOMEN’S SEXUAL HEALTH COMPANY CHANGES NAME IN PREPARATION FOR MARKET ENTRY

October 16, 2009

FLEXION THERAPEUTICS RAISES $33 MILLION IN SERIES A FINANCING

October 15, 2009

KALOBIOS’ KB001 ANTIBODY SHOWS ENCOURAGING SAFETY AND ACTIVITY IN NEW APPROACH TO FIGHTING PSEUDOMONAS INFECTION IN CYSTIC FIBROSIS PATIENTS

October 14, 2009

NEW DRUG DISCOVERY COMPANY ENVOY THERAPEUTICS RAISES $8 MILLION

October 07, 2009

RELYPSA INITIATES PHASE 2B CLINICAL TRIAL OF RLY5016 FOR THE PREVENTION OF HYPERKALEMIA IN HEART FAILURE PATIENTS

September 18, 2009

AMBRX STRIKES DEAL WITH WYETH (SOON-TO-BE PFIZER) TO MAKE ANTIBODY DRUGS

September 14, 2009

WILDCAT DISCOVERY TECHNOLOGIES SELECTED BY ALWAYSON AS A GOINGGREEN TOP 100 WINNER

September 14, 2009

ACHAOGEN ANNOUNCES ACHN-490 CLINICAL DATA AT THE 49TH ANNUAL ICAAC MEETING

August 25, 2009

ACHAOGEN APPOINTS JOHN C. DOYLE TO THE NEWLY CREATED POSITION OF CHIEF OPERATING OFFICER

August 10, 2009

IKARIA TO IN-LICENSE WORLDWIDE RIGHTS TO INVESTIGATIONAL PORTFOLIO FROM FIBREX MEDICAL

July 06, 2009

IKARIA TO IN-LICENSE BIOLINERX’S BL-1040

June 29, 2009

FIERCEBIOTECH NAMES ACHAOGEN AS ONE OF THE “FIERCE 15” BIOTECH COMPANIES OF 2009

June 12, 2009

FDA ACCEPTS FINAL SECTION OF NDA FILING FOR LUCASSIN®

June 01, 2009

ENTREMED PRESENTS RESULTS OF ENMD-2076 PHASE 1 STUDY IN ADVANCED CANCER PATIENTS

May 16, 2009

ACHAOGEN DATA SHOW RAPID RISE IN RATES OF RESISTANCE TO CURRENT ANTIBIOTICS; ILLUSTRATE GLOBAL NEED FOR NEW, WELL-TOLERATED AGENTS TO ADDRESS VARIED MECHANISMS OF RESISTANCE

May 13, 2009

SYNOSIA THERAPEUTICS BEGINS PHASE I TRIAL OF A NEW GENERATION TREATMENT FOR COGNITIVE IMPAIRMENT

May 01, 2009

PULMATRIX ANNOUNCES PH 1B/2A CLINICAL TRIAL OF NOVEL ICALM THERAPY FOR FLU

March 10, 2009

SYNOSIA ANNOUNCES SECOND AGREEMENT WITH ROCHE

March 09, 2009

IGENICA APPOINTS DR. MIKE ROTHE AS CEO AFTER CLOSING SERIES A FINANCING

March 03, 2009

ACHAOGEN SIGNS $26.6 MILLION CONTRACT WITH NIAID FOR DEVELOPMENT OF NEW THERAPY TO TREAT RESISTANT STRAINS OF NIAID CATEGORY A AND B PRIORITY PATHOGENS

February 24, 2009

PEARL THERAPEUTICS SECURES $8 MILLION IN DEBT FINANCING

February 09, 2009

ENTREMED PRESENTS INITIAL CLINICAL RESULTS FOR ENMD-2076

February 09, 2009

BIOTECHS BEFRIEND NON-DILUTIVE FUNDS

February 03, 2009

ACHAOGEN INITIATES PHASE 1 TRIAL OF ACHN-490 FOR TREATMENT OF MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS

January 08, 2009

ACHAOGEN RECEIVES ₤4.1 MILLION AWARD FROM THE WELLCOME TRUST TO ADVANCE ITS NEOGLYCOSIDES PORTFOLIO

January 07, 2009

SYNOSIA THERAPEUTICS RAISES CHF32 MILLION IN SERIES B PRIVATE FINANCING

January 07, 2009

ANAPHORE, INC. ANNOUNCES $25 MILLION SERIES A FINANCING